FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction in senescent cell research. Full Kiwi Peps profile inside.
The FOXO4-DRI peptide is a D-retro-inverso (DRI) analog of a FOXO4 fragment, designed to competitively disrupt the FOXO4–p53 interaction that is upregulated in senescent cells. Published in-vitro research characterises FOXO4-DRI as a proof-of-concept senolytic reference peptide, and it is one of the most frequently cited compounds in cellular-senescence research panels.
FOXO4-DRI peptide at a glance
| Attribute | Specification |
|---|---|
| Backbone | D-retro-inverso (DRI) FOXO4 fragment |
| Design principle | Proteolytic resistance via D-amino-acid backbone reversal |
| Target interaction | FOXO4–p53 |
| Primary research context | Cellular senescence, senolytic references |
| Documented purity spec | ≥ 98% HPLC |
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
FOXO4-DRI peptide FAQ
What is the FOXO4-DRI peptide?
FOXO4-DRI is a D-retro-inverso analog of a FOXO4 fragment designed to competitively disrupt the FOXO4–p53 interaction, cited in published cellular-senescence research as a proof-of-concept senolytic reference.
Why is the D-retro-inverso backbone used?
The DRI backbone reverses sequence direction and uses D-amino acids, producing proteolytic resistance while preserving side-chain topology relevant to protein-protein interaction disruption.
Where can New Zealand researchers buy FOXO4-DRI?
Kiwi Peps supplies FOXO4-DRI at ≥98% HPLC purity with third-party COA and same-day domestic dispatch. Research use only.
